2950-3299

Molecular Therapy Oncology

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 476 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact476 DOIs
2

Attach ORCID iDs across 62 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact62 DOIs
3

Deposit reference lists for 24 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact24 DOIs

DOIs for this ISSN

Showing the top 5 of 476 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Comprehensive machine learning-based integration develops a… (10.1016/j.omton.2024.200838)
Abstract ORCID
53.96 11
2 Dynamic changes of the immune microenvironment in the develo… (10.1016/j.omton.2024.200849)
Abstract ORCID
52.07 10
3 Genetically stable multi-gene edited iPSCs-derived NK cells… (10.1016/j.omton.2024.200885)
Abstract ORCID
47.71 8
4 Bulk and single-cell transcriptomics identify gene signature… (10.1016/j.omton.2024.200870)
Abstract ORCID
45.15 7
5 Promising immunotherapy targets: TIM3, LAG3, and TIGIT joine… (10.1016/j.omton.2024.200773)
Abstract
43.11 52
6 Toll-like receptor 4 signaling activation domains promote CA… (10.1016/j.omton.2024.200815)
Abstract ORCID
42.25 6
7 Minute virus of mice shows oncolytic activity against pancre… (10.1016/j.omton.2024.200780)
Abstract ORCID
38.91 5
8 DARPin-fused T cell engager for adenovirus-mediated cancer t… (10.1016/j.omton.2024.200821)
Abstract ORCID
38.91 5
9 FOXJ3, a novel tumor suppressor in neuroblastoma (10.1016/j.omton.2024.200914)
Abstract ORCID
38.91 5
10 miRNA-dependent resistance mechanisms to anti-hormonal thera… (10.1016/j.omton.2025.200941)
Abstract ORCID
38.91 5
11 Cost-effective strategies for CAR-T cell therapy manufacturi… (10.1016/j.omton.2025.200980)
Abstract
38.29 33
12 Bispecific CAR-T cells targeting FAP and GPC3 have the poten… (10.1016/j.omton.2024.200817)
Abstract
37.28 30
13 Genetic dysregulation of EP300 in cancers in light of cancer… (10.1016/j.omton.2024.200871)
Abstract
34.95 24
14 CXCL10-induced chemotaxis of ex vivo-expanded natural killer… (10.1016/j.omton.2025.201051)
Abstract ORCID
34.95 4
15 TROP2 is highly expressed in triple-negative breast cancer C… (10.1016/j.omton.2024.200762)
Abstract
33.06 20
16 Cancer testis antigens: Emerging therapeutic targets leverag… (10.1016/j.omton.2024.200768)
Abstract
31.97 18
17 CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as supe… (10.1016/j.omton.2024.200797)
Abstract
31.97 18
18 Empowering pancreatic tumor homing with augmented anti-tumor… (10.1016/j.omton.2024.200777)
Abstract
30.76 16
19 Solid cancer-directed CAR T cell therapy that attacks both t… (10.1016/j.omton.2024.200891)
Abstract
30.10 15
20 Allele-specific depletion of GNAQQ209L via siRNA or an rAAV2… (10.1016/j.omton.2025.201020)
Abstract ORCID
30.10 3
21 The crosstalk between non-coding RNAs and cell-cycle events:… (10.1016/j.omton.2024.200785)
Abstract
29.40 14
22 Emerging delivery strategy for oncolytic virotherapy (10.1016/j.omton.2024.200809)
Abstract
29.40 14
23 Oncolytic vesicular stomatitis virus alone or in combination… (10.1016/j.omton.2024.200826)
Abstract
29.40 14
24 Unveiling promising targets in gastric cancer therapy: A com… (10.1016/j.omton.2024.200857)
Abstract
29.40 14
25 Shared neoantigens for cancer immunotherapy (10.1016/j.omton.2025.200978)
Abstract
29.40 14
26 Discovery and preclinical development of a therapeutically a… (10.1016/j.omton.2024.200775)
Abstract
27.85 12
27 Co-stimulation of CD28/CD40 signaling molecule potentiates C… (10.1016/j.omton.2024.200837)
Abstract
27.85 12
28 Structural insights and clinical advances in small-molecule… (10.1016/j.omton.2025.200945)
Abstract
27.85 12
29 Targeting the ribosome to treat multiple myeloma (10.1016/j.omton.2024.200771)
Abstract
26.98 11
30 Enhanced therapeutic efficacy for glioblastoma immunotherapy… (10.1016/j.omton.2024.200799)
Abstract
26.98 11
31 Harnessing exosomes as a platform for drug delivery in breas… (10.1016/j.omton.2024.200800)
Abstract
26.98 11
32 Oncolytic virus V937 in combination with PD-1 blockade thera… (10.1016/j.omton.2024.200807)
Abstract
26.98 11
33 Point-of-care manufacturing of anti-CD19 CAR-T cells using a… (10.1016/j.omton.2024.200889)
Abstract
26.98 11
34 Combinatorial immunotherapy with anti-ROR1 CAR NK cells and… (10.1016/j.omton.2024.200927)
Abstract
26.98 11
35 Emerging therapeutic approaches for peritoneal metastases fr… (10.1016/j.omton.2024.200767)
Abstract
26.03 10
36 Rejection resistant CD30.CAR-modified Epstein-Barr virus-spe… (10.1016/j.omton.2024.200814)
Abstract
26.03 10
37 TYRP1 directed CAR T cells control tumor progression in prec… (10.1016/j.omton.2024.200862)
Abstract
26.03 10
38 Oncolytic viruses alter the biogenesis of tumor extracellula… (10.1016/j.omton.2024.200887)
Abstract
26.03 10
39 CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6… (10.1016/j.omton.2024.200892)
Abstract
26.03 10
40 Noncoding RNA landscape and their emerging roles as biomarke… (10.1016/j.omton.2024.200782)
Abstract
25.00 9
41 Gut microbiota composition is associated with the efficacy o… (10.1016/j.omton.2024.200787)
Abstract
25.00 9
42 Functional remodeling of intraperitoneal macrophages by onco… (10.1016/j.omton.2024.200806)
Abstract
25.00 9
43 Translation of oncolytic viruses in sarcoma (10.1016/j.omton.2024.200822)
Abstract
25.00 9
44 CAR-T cell therapy: Advances in digestive system malignant t… (10.1016/j.omton.2024.200872)
Abstract
25.00 9
45 Development of multivalent CAR T cells as dual immunotherapy… (10.1016/j.omton.2025.200944)
Abstract
25.00 9
46 CD147-CAR-NK cell therapy shows minimal toxicities in human… (10.1016/j.omton.2025.200957)
Abstract
25.00 9
47 A dual-luciferase bioluminescence system for the assessment… (10.1016/j.omton.2024.200763)
Abstract
23.86 8
48 MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder… (10.1016/j.omton.2024.200765)
Abstract
23.86 8
49 Development of gemcitabine-modified miRNA mimics as cancer t… (10.1016/j.omton.2024.200769)
Abstract
23.86 8
50 Advances in cell-based delivery of oncolytic viruses as ther… (10.1016/j.omton.2024.200788)
Abstract
23.86 8